The Clinic Study About Serum α₁-Antitrypsin Change In Chronic Hepatitis Disease And Lung Disease

Objective:α₁-AT is a glycoprotein produced mainly in the liver, but its main function is to protect the lung against proteolytic damage from neutrophil elastase.Its deficiency can lead to many clinical manifestations, most commonly chronic obstructive pulmonary disease in the form of emphysema. However, patients with this genetic disorder may also develop dysfunctions of other organs such as the liver and/or skin. We will study theα₁-AT D clinic value on change of adult with chronic hepatitis disease and lung disease. Methods: All persons who were included by 34 chronic hepatitis(CH)and 23 no cause hepatitis and79 healthy persons(H) were collected. Other, there are 7 autoimmunity liver disease.α₁-AT was detected with ELISA.Results:The difference between healthy persons and cryptogenic chronic hepatitis was statistically significant; The difference between healthy persons and autoimmunity liver disease was statistically significant; The difference between healthy persons and chronic hepatitis was statistically similar..Conclusions:.Alpha-1 antitrypsin deficiency is an auto-somal recessive disorder that can lead to chronic pulmonary disease and liver cirrhosis. The liver disease is caused by accumulation of an abnormal, polymerised protein. Deficient phenotypes are present worldwide. Homozygous deficiency in children can cause neonatal hepatitis. In adults homozygous patients are at risk for developing end-stage liver diseases, cirrhosis and hepatocellular carcinoma..α₁-AT serum levels may be used, but phenotype is crucial, as serum levels may not reflect true deficiencies (as inflammation serum levels can be falsely normal). Especially in cryptogenic chronic liver disease and liver disease that deteriorates faster than may be expected,α₁-AT deficiency may be of clinical significance as a (co)-factor. Clinical research is needed inα₁-AT -related liver disease to investigate the association between heterozygousα₁-AT deficiency and the presentation and course of liver diseases. We believe that the current data are insufficient to decide on the pros and cons of screening on hepatocellular carcinoma inα₁-AT deficiency.We should screenα₁-AT serum for cryptogenic chronic liver disease so that we can find to associate between cause and AAT deficiency for these persons .